The European Medicines Agency (EMA) on April 8, 2026, launched an image campaign aimed at raising awareness about veterinary medicine safety for the year 2026. The campaign targets veterinarians, animal owners, and the veterinary pharmaceutical industry, seeking to promote responsible use and reporting of adverse events.
The campaign, announced by EMA's Veterinary Medicines Division, is a public awareness initiative rather than a regulatory action. It includes visual materials and digital outreach designed to encourage stakeholders to report suspected adverse reactions and to follow best practices in veterinary pharmacovigilance. The campaign does not introduce new numerical targets or binding commitments.
This initiative follows the EMA Pharmacovigilance Risk Assessment Committee's (PRAC) adoption of new drug safety monitoring recommendations on April 7, 2026, which proposed stricter requirements for reporting adverse drug reactions and implementing risk management plans for human medicines. While that PRAC opinion focused on human drugs, the new veterinary campaign extends the agency's safety awareness efforts to the animal health sector.
The campaign also builds on EMA's broader transparency and stakeholder engagement efforts, as outlined in its April 7, 2026 report on 2025 public engagement activities, which highlighted initiatives such as public consultations and workshops with healthcare professionals. The veterinary campaign similarly aims to foster dialogue and trust among stakeholders.
Policy Orientations and Trade-offs The campaign balances the need for increased safety monitoring with the potential burden on veterinarians and animal owners to report adverse events. By promoting voluntary reporting, it avoids imposing mandatory requirements but relies on stakeholder cooperation to improve data collection. This approach may enhance safety without adding regulatory costs, but could result in underreporting compared to mandatory systems.
Impact on Stakeholders - Veterinary pharmaceutical companies: May face increased scrutiny and reputational pressure to ensure product safety, but no new compliance costs. - Veterinarians: Encouraged to report adverse events, potentially increasing administrative workload without direct compensation. - Animal owners: Benefit from greater awareness of medicine safety, leading to better-informed decisions. - National competent authorities: May receive more adverse event reports, improving pharmacovigilance data, but no new obligations.
Expected Institutional Follow-up The campaign is expected to run throughout 2026, with EMA monitoring engagement metrics. No immediate regulatory changes are anticipated, but the campaign may inform future veterinary pharmacovigilance guidelines.
← Atlas › News › Agri-food